RT Journal Article
SR Electronic
T1 Bortezomib-induced neuropathy in multiple myeloma manifesting as foot drop due to peroneal nerve palsy
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e260909
DO 10.1136/bcr-2024-260909
VO 17
IS 9
A1 Raveendran, Ciniraj
A1 Sunaisha Ashrafudeen, Sherin
A1 Yadev, IP
YR 2024
UL http://casereports.bmj.com/content/17/9/e260909.abstract
AB We present the case of a man in his 50s with multiple myeloma who developed foot drop after receiving bortezomib-dexamethasone combination chemotherapy. Diagnostic evaluations, including haematological parameters, nerve conduction studies and imaging, were performed to confirm the diagnosis and assess the extent of neuropathy. He was managed conservatively with analgesics and vitamin supplements, and bortezomib was temporarily withheld. The neuropathy gradually improved, and bortezomib was successfully reintroduced without recurrence of foot drop. Bortezomib-induced foot drop is a rare complication of bortezomib-based therapy in patients with multiple myeloma. Early recognition and intervention are crucial to minimise impact on quality of life. This case report emphasises the safe reintroduction of bortezomib post-neuropathy resolution, emphasising the importance of early recognition and multidisciplinary management.